Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in vitro diagnostic (IVD) specialist in China, to develop a new model that combines allergy detection, desensitization treatment, and Internet+ technologies. The collaboration aims to create a comprehensive approach to allergy management without disclosing financial details.
HOB Biotech’s Expertise and the Partnership’s Focus
As China’s first and only listed company specializing in allergy detection, HOB Biotech Group is dedicated to the research, development, and manufacturing of IVD reagents for allergy and autoimmune disease diagnostics. The partnership will leverage the combined strengths of both companies, working with a team of authoritative medical experts to promote a “four in one” scientific model based on allergen testing. This model will be disseminated through various popular science education methods, including live streaming, video, image, text, and academic literature interpretation, to enhance public awareness of allergic diseases.
Enhancing Public Awareness and Providing Individualized Services
The collaboration will focus on raising public awareness of allergic diseases and providing individualized services that combine patient complaints. By依托“allergy detection” centers and Internet hospitals, Baidu Health and HOB Biotech will offer personalized services that cater to the specific needs of patients.
Improving Patient-Doctor Matching and Resource Connectivity
Furthermore, Baidu Health and HOB Biotech will work towards the efficient and accurate matching of patients, doctors, hospitals, and testing institutions. This will be achieved by utilizing Baidu Health’s precise doctor-patient matching engine, which will enable “precise patient differentiation and guidance.” The goal is to enhance the connection efficiency between allergic patients and authoritative medical resources, ensuring that patients receive the best possible care and guidance.-Fineline Info & Tech
